Stellar Biotechnologies Inc (OTCMKTS:SBOTF) seems to have strong support at $1 and is making another move up off it now. SBOTF is a stock with a history of big moves running from $0.60 to highs of $2.36 back in September.
SBOTF is a Company that has been around for many years and was originally listed on the notorious Vancouver Stock Exchange. The Company is dually listed on the OTCBB and Canada’s TSX Venture Exchange where it trades under the symbol KLH. The recent surge in massive volume and upside comes on the heels of a significant promotion by Stansberry, Agora, Oxford and several others.
Stellar Biotechnologies Inc (OTCMKTS:SBOTF) is the leader in sustainable manufacture of Keyhole Limpet Hemocyanin (KLH), an important immune-stimulating protein used in wide-ranging therapeutic and diagnostic markets. KLH is both an active pharmaceutical ingredient (API) in many new immunotherapies (targeting cancer, infectious diseases, and immune disorders) as well as a finished product for measuring immune status.
To Find out the inside Scoop on SBOTF Subscribe to Microcapdaily.com Right Now by entering your Email in the box below
The Company is unique in its proprietary methods, facilities, and KLH technology. We are committed to meeting the growing demand for commercial-scale supplies of GMP grade KLH, ensuring environmentally sound KLH production, and developing KLH-based active immunotherapies.
According to a recent email from Oil & Energy Investor ¨SBOTF has a monopoly over a breakthrough called living metal. Based on the 124 advanced clinical trials currently underway, it’s now believed that this discovery could be at the center of a series of miraculous treatments for Alzheimer’s, cancer, arthritis, and much more.¨
Back in July SBOTF reported Third Quarter 2014 Financial Results; Cash and cash equivalents as of May 31, 2014 were $14.8 million, compared to $ 7.9 million at year-end August 31, 2013. Revenues were $102,581 in the third quarter and $252,848 for the nine months ended May 31, 2014 compared to $73,214 and $250,422 in the comparable periods in 2013.
On September 5 SBOTF announced Stellar Biotechnologies Analyst Report; Early Mover in Fast Growing Immunotherapy Market by BrokerBank Securities, Inc.
Stellar Biotechnologies Inc (OTCMKTS:SBOTF) is an emerging contender in sustainable manufacture of Keyhole Limpet Hemocyanin (KLH), an important immune-stimulating protein used in wide-ranging therapeutic and diagnostic markets. KLH is both an active pharmaceutical ingredient (API) in many new immunotherapies (targeting cancer, immune disorders, and infectious diseases) as well as a finished product for measuring immune status. Stellar Biotechnologies is unique in its proprietary methods, facilities, and KLH technology.
We have a Monster Pick Coming. Subscribe Right Now!
The Company’s KLH protein is so unique because it can be sourced from the blood of only one rare sea animal, the California Keyhole Limpet which SBOTF farms in its own facility. The Keyhole Limpet can only be found off the coast of central California to Northern Baja. Stellar’s headquarters and aquaculture facility are situated in the center of those two locations. This is certainly an advantage that creates entry barriers but also creates big systemic vulnerability issues as well. How long it takes at maturity to produce the material and the ultimate quality level are still to be learned. This can be a decided advantage for aggressive traders and speculators but must be carefully considered as a risk for longer term investors.
Currently trading at a $90 million market valuation SBOTF has $13.4 million in the treasury and is fully funded going forward. SBOTF seems to have strong support at $1 and is making another move up off it now. The stock made a spectacular run earlier this year on the promotion from Stansberry, Agora, Oxford and several others. As the stock once again reverses up off $1 investors are taking notice.
Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!
Disclosure: we hold no position in SBOTF either long or short and we have not been compensated for this article.